To view all of the conflicts of interest for the NCCN Guidelines panel, go to /guidelines/guidelines-panels-and-disclosure/disclosure-panels and serving as a scientific advisor for Advarra, Inc., CareDx, GlaxoSmithKline, Janssen Pharmaceutica Products, LP, and sanofi-aventis U.S. Mark Schroeder, MD, Panel Member, has disclosed receiving consulting fees from Equillium, Inc., Incyte Corporation, Inmagene Biopharmaceuticals, Janssen Pharmaceutica Products, LP, and sanofi-aventis U.S. Mohamed Kharfan Dabaja, MD, Panel Member, has disclosed receiving grant/research support from Bristol Myers Squibb Company and Novartis Pharmaceuticals Corporation. All of the relevant financial relationships listed for these individuals have been mitigated.Īyman Saad, MD, Panel Chair, has disclosed receiving grant/research support from Kadmon Corporation and Orca Bio receiving consulting fees from Kite Pharma and receiving royalty income from IN8bio Inc.Īlison Loren, MD, MSCE, Panel Vice Chair, has disclosed receiving grant/research support from Equillium, Inc.Īreej El-Jawahri, MD, Panel Member, has disclosed receiving consulting fees from GlaxoSmithKline, Incyte Corporation, and Novartis Pharmaceuticals Corporation. The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. Pluchino, PhD, Oncology Scientist/Medical Writer, NCCN The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.įrankie Algieri, Guidelines Layout Specialist, NCCN Individuals Who Provided Content Development and/or Authorship Assistance: If you have any questions, please email date: FebruExpiration date: February 10, 2024 Your credit cannot be reported without this information. Before completing these requirements, be sure your NCCN profile has been updated with your NAPB e-profile ID and date of birth. Continuing pharmacy education credit is reported to the CPE Monitor once you have completed the posttest and evaluation and claimed your credits. Pharmacists: You must complete the posttest and evaluation within 30 days of the activity. To participate in this journal CE activity: (1) review the educational content (2) take the posttest with a 66% minimum passing score and complete the evaluation at and (3) view/print certificate. PAs should only claim credit commensurate with the extent of their participation.Īll clinicians completing this activity will be issued a certificate of participation. Approval is valid until February 10, 2024. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs: NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. Pharmacists: NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. Nurses: NCCN designates this educational activity for a maximum of 1.0 contact hour. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians: NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease-a major complication of allogeneic HCT-to enable the patient and clinician to assess management options in the context of an individual patient’s condition. HCT is a potentially curative treatment option for patients with certain types of malignancies however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |